Modeling SARS-CoV-2: Comparative Pathology in Rhesus Macaque and Golden Syrian Hamster Models.


Journal

Toxicologic pathology
ISSN: 1533-1601
Titre abrégé: Toxicol Pathol
Pays: United States
ID NLM: 7905907

Informations de publication

Date de publication:
04 2022
Historique:
pubmed: 8 2 2022
medline: 25 5 2022
entrez: 7 2 2022
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) in humans has a wide range of presentations, ranging from asymptomatic or mild symptoms to severe illness. Suitable animal models mimicking varying degrees of clinical disease manifestations could expedite development of therapeutics and vaccines for COVID-19. Here we demonstrate that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection resulted in subclinical disease in rhesus macaques with mild pneumonia and clinical disease in Syrian hamsters with severe pneumonia. SARS-CoV-2 infection was confirmed by formalin-fixed, paraffin-embedded (FFPE) polymerase chain reaction (PCR), immunohistochemistry, or in situ hybridization. Replicating virus in the lungs was identified using in situ hybridization or virus plaque forming assays. Viral encephalitis, reported in some COVID-19 patients, was identified in one macaque and was confirmed with immunohistochemistry. There was no evidence of encephalitis in hamsters. Severity and distribution of lung inflammation were substantially more in hamsters compared with macaques and exhibited vascular changes and virus-induced cytopathic changes as seen in COVID-19 patients. Neither the hamster nor macaque models demonstrated evidence for multisystemic inflammatory syndrome (MIS). Data presented here demonstrate that macaques may be appropriate for mechanistic studies of mild asymptomatic COVID-19 pneumonia and COVID-19-associated encephalitis, whereas Syrian hamsters may be more suited to study severe COVID-19 pneumonia.

Identifiants

pubmed: 35128980
doi: 10.1177/01926233211072767
pmc: PMC8819578
doi:

Substances chimiques

COVID-19 Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

280-293

Subventions

Organisme : NIH HHS
ID : P51 OD011133
Pays : United States

Références

Signal Transduct Target Ther. 2021 Apr 24;6(1):169
pubmed: 33895780
Viruses. 2021 Jan 19;13(1):
pubmed: 33477869
Nature. 2020 Oct;586(7830):509-515
pubmed: 32967005
Acta Neuropathol. 2021 Jun;141(6):809-822
pubmed: 33903954
Clin Infect Dis. 2020 Dec 3;71(9):2428-2446
pubmed: 32215622
Viruses. 2021 Apr 08;13(4):
pubmed: 33918079
JAMA Netw Open. 2021 May 3;4(5):e2112131
pubmed: 33974053
Nature. 2020 Jul;583(7818):834-838
pubmed: 32408338
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
Science. 2020 May 29;368(6494):1012-1015
pubmed: 32303590
Science. 2020 May 29;368(6494):1016-1020
pubmed: 32269068
Nat Med. 2020 Nov;26(11):1694-1700
pubmed: 32884153
Nature. 2020 Sep;585(7824):268-272
pubmed: 32396922
Mucosal Immunol. 2020 Nov;13(6):877-891
pubmed: 32820248
Curr Protoc Microbiol. 2020 Jun;57(1):ecpmc105
pubmed: 32475066
Am J Pathol. 1987 Nov;129(2):345-52
pubmed: 2823615
J Anat. 1978 Mar;125(Pt 3):527-53
pubmed: 640957
Animal Model Exp Med. 2020 Mar 30;3(1):93-97
pubmed: 32318665
Nat Microbiol. 2021 Jan;6(1):73-86
pubmed: 33340034
Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L570-9
pubmed: 17586691
Mod Pathol. 2020 Nov;33(11):2128-2138
pubmed: 32572155
Lancet. 2020 May 2;395(10234):1417-1418
pubmed: 32325026
Bosn J Basic Med Sci. 2020 Aug 03;20(3):283-292
pubmed: 32530389
Cell. 2020 Nov 25;183(5):1354-1366.e13
pubmed: 33065030
Emerg Microbes Infect. 2020 Dec;9(1):2673-2684
pubmed: 33251966
Virol Sin. 2020 Jun;35(3):290-304
pubmed: 32607866
ACS Chem Neurosci. 2020 Apr 1;11(7):995-998
pubmed: 32167747
Nat Commun. 2020 Sep 2;11(1):4400
pubmed: 32879306
J Virol. 2002 Apr;76(8):3646-58
pubmed: 11907204
Case Rep Neurol. 2020 Nov 2;12(3):373-377
pubmed: 33250751
Wien Klin Wochenschr. 2021 Apr;133(7-8):377-382
pubmed: 33242148
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
Nature. 2021 Apr;592(7853):283-289
pubmed: 33524990
Int J Mol Sci. 2021 Mar 05;22(5):
pubmed: 33807915
Infection. 2021 Feb;49(1):117-126
pubmed: 33231841
Front Pharmacol. 2021 Jan 14;11:579330
pubmed: 33568991
EMBO J. 2020 Dec 1;39(23):e106267
pubmed: 33051876
J Infect Dis. 2020 Oct 13;222(10):1596-1600
pubmed: 32745172
Nature. 2020 Sep;585(7824):273-276
pubmed: 32516797
Signal Transduct Target Ther. 2020 Oct 19;5(1):157
pubmed: 32814760
EBioMedicine. 2020 Aug;58:102907
pubmed: 32771682

Auteurs

Shambhunath Choudhary (S)

Pfizer, Pearl River, New York, USA.

Isis Kanevsky (I)

Pfizer, Pearl River, New York, USA.

Soner Yildiz (S)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Rani S Sellers (RS)

Pfizer, Pearl River, New York, USA.

Kena A Swanson (KA)

Pfizer, Pearl River, New York, USA.

Tania Franks (T)

Pfizer, Groton, New York, USA.

Raveen Rathnasinghe (R)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Raquel Munoz-Moreno (R)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Sonia Jangra (S)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Olga Gonzalez (O)

Texas Biomedical Research Institute, San Antonio, Texas, USA.

Philip Meade (P)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Timothy Coskran (T)

Pfizer, Groton, New York, USA.

Jessie Qian (J)

Pfizer, Groton, New York, USA.

Thomas A Lanz (TA)

Pfizer, Groton, New York, USA.

Jillian G Johnson (JG)

Pfizer, Groton, New York, USA.

Cassandra A Tierney (CA)

Pfizer, Groton, New York, USA.

Justin D Smith (JD)

Pfizer, Groton, New York, USA.

Kristin Tompkins (K)

Pfizer, Pearl River, New York, USA.

Arthur Illenberger (A)

Pfizer, Pearl River, New York, USA.

Paula Corts (P)

Pfizer, Pearl River, New York, USA.

Tara Ciolino (T)

Pfizer, Pearl River, New York, USA.

Philip R Dormitzer (PR)

Pfizer, Pearl River, New York, USA.

Edward J Dick (EJ)

Texas Biomedical Research Institute, San Antonio, Texas, USA.

Vinay Shivanna (V)

Texas Biomedical Research Institute, San Antonio, Texas, USA.

Shannan Hall-Ursone (S)

Texas Biomedical Research Institute, San Antonio, Texas, USA.

Journey Cole (J)

Texas Biomedical Research Institute, San Antonio, Texas, USA.

Deepak Kaushal (D)

Texas Biomedical Research Institute, San Antonio, Texas, USA.

Jane A Fontenot (JA)

New Iberia Research Center, New Iberia, Louisiana, USA.

Carles Martinez-Romero (C)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Meagan McMahon (M)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Florian Krammer (F)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Michael Schotsaert (M)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Adolfo García-Sastre (A)

Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH